NCT00798720View on ClinicalTrials.gov

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Carcinoma, Non Small Cell Lung
Interventions
DRUG

vorinostat

400 mg by mouth once daily for days 1-14 of each 21 day cycle

DRUG

bortezomib

1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Wisconsin, Madison

OTHER